Augmenting Flortaucipir Dosimetry Estimates

Avid Pharmaceuticals

Status and phase: Completed; Phase 1

Conditions: Alzheimer's Disease

Treatments: Drug: Flortaucipir F18

Study type: Interventional

Funder types: Industry

Identifiers

NCT02336360

18F-AV-1451-A15

Details and patient eligibility

About

This study will obtain data from urine in subjects administered flortaucipir in an Avid-sponsored study to augment the calculation of radiation dosimetry estimates.

Enrollment: 6 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Subjects who passed screening in an Avid-sponsored study in which flortaucipir will be administered

Exclusion criteria

• Subjects who have withdrawn informed consent
• Investigator or sponsor believes it is in the best interest of the subject to be removed from the trials

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

6 participants in 1 patient group

Urine Analysis

Experimental group

Description:

Urine will be collected from subjects administered flortaucipir in an Avid-sponsored study to determine the amount of radioactivity excreted in urine.

Treatment:

Drug: Flortaucipir F18